Explore ›
Finding
Finding
adverse
The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).
| Effect size | 94% vs 56% |
| Comparator | 1 cycle of bridging chemotherapy prior to CD19-specific CAR T cell infusion |
| Effect summary | adverse; 94% vs 56% |
| Adverse events | grade >=3 infections 94% versus 56% |
Connected entities
Interventions
Outcomes
Source
PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia